Patent intelligence · US
US 11613551
Aminoglycoside derivatives and uses thereof in treating genetic disorders
Aminoglycoside derivatives and uses thereof in treating genetic disorders
Patent details — US 11613551
- Jurisdiction
- US
- Status
- granted
- Grant date
- Mar 28, 2023
- Expiration
- Mar 23, 2043
- Applicant
- ELOXX PHARMACEUTICALS LTD.
- Claims
- 11
- CPC classes
- A61P, A61P13/12, A61P17/00, A61P21/00
Quick answer
US 11613551 (Aminoglycoside derivatives and uses thereof in treating genetic disorders) is held by ELOXX PHARMACEUTICALS LTD.. Status: granted. Granted Mar 28, 2023. Expires Mar 23, 2043 (17 years remaining) — relevant for patent-cliff and LOE planning.
Key facts
- Applicant
- ELOXX PHARMACEUTICALS LTD.
- Grant date
- Expiration
- Claims
- 11
- CPC classes
- A61P, A61P13/12, A61P17/00, A61P21/00, A61P21/04, A61P27/02
More from ELOXX PHARMACEUTICALS LTD.
Related pharmaceutical patents in our USPTO index.
-
US 11786539
Aminoglycoside derivatives and uses thereof in treating genetic disorders
granted -
US 11306115
Aminoglycoside derivatives and uses thereof in treating genetic disorders
granted -
US 10899785
Aminoglycoside derivatives and uses thereof in treating genetic disorders
granted -
US 10786520
Aminoglycoside derivatives and uses thereof in treating genetic disorders
granted -
US 10576095
Use of aminoglycoside analogs in the treatment of Rett syndrome
granted
Frequently asked questions
What is US patent 11613551?
US 11613551 (Aminoglycoside derivatives and uses thereof in treating genetic disorders) is held by ELOXX PHARMACEUTICALS LTD.. Status: granted. Granted Mar 28, 2023. Expires Mar 23, 2043 (17 years remaining) — relevant for patent-cliff and LOE planning.
Who owns US 11613551?
ELOXX PHARMACEUTICALS LTD. is listed as the applicant in USPTO PatentsView records indexed by NovaPharmaNews. We track 6 pharmaceutical patents for this assignee.
When does US 11613551 expire?
Our index shows an expiration date of Mar 23, 2043 (17 years from today). Confirm material dates against USPTO, FDA Orange Book, or qualified counsel before contractual decisions.